{"id":"W3045546553","doi":"10.1136/annrheumdis-2020-eular.994","title":"AB0774 TIME TO RESPONSE FOR CLINICAL AND PATIENT-REPORTED OUTCOMES IN PATIENTS WITH PSORIATIC ARTHRITIS TREATED WITH TOFACITINIB, ADALIMUMAB OR PLACEBO","year":2020,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Rheumatoid Arthritis Research and Therapies","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"ca_institutions":"Pfizer (Canada); University of Toronto","funders":"","keywords":"Tofacitinib; Medicine; Adalimumab; Janus kinase inhibitor; Psoriatic arthritis; Internal medicine; Placebo; Clinical trial; Psoriasis; Clinical endpoint; Dermatology; Arthritis; Rheumatoid arthritis; Alternative medicine","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00157077,0.0003947302,0.001386301,0.0004344673,0.0002695968,0.0006518799,0.0002880729,0.0007280265,0.002459221],"category_scores_gemma":[0.003147592,0.0001579522,0.001517737,0.000424482,0.0002045233,0.000729601,0.0002463709,0.001147775,0.0004088561],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006070524,"about_ca_system_score_gemma":0.0005749968,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001444452,"about_ca_topic_score_gemma":0.001688448,"domain_scores_codex":[0.999044,0.0003675524,0.00007489281,0.0001339971,0.0001685817,0.0002109364],"domain_scores_gemma":[0.9985412,0.0006620015,0.0003775242,0.00004242864,0.0001105767,0.0002661989],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.4784328,0.00382905,0.3628022,0.0009421987,0.006091919,0.0005880966,0.0002451907,0.004718536,0.00663735,0.0004898413,0.005771512,0.1294513],"study_design_scores_gemma":[0.01627045,0.05606209,0.913311,0.000132501,0.003577545,0.0005949846,0.0002278764,0.005235623,0.001169216,0.0005458873,0.002769867,0.0001029002],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9926149,0.003750949,0.0001313868,0.0002805613,0.000134328,0.00005064223,0.0007329965,0.00002764202,0.002276651],"genre_scores_gemma":[0.9978217,0.0004303202,0.00008586146,0.0001693006,0.0001021186,0.00005899782,0.0006938683,0.000003204728,0.0006346494],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002459221,"threshold_uncertainty_score":0.008307159,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04316765185162938,"score_gpt":0.3293543067127573,"score_spread":0.2861866548611279,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}